Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Innoviva Inc (NQ: INVA ) 16.36 +0.03 (+0.18%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 310,874 Open 16.26 Bid (Size) 16.08 (1) Ask (Size) 16.60 (1) Prev. Close 16.33 Today's Range 16.21 - 16.42 52wk Range 12.22 - 16.86 Shares Outstanding 65,504,384 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge June 27, 2024 Discover three high-growth stock picks set for unprecedented surges in the metals, marine transportation, and pharmaceutical industries. Via InvestorPlace Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs June 18, 2024 Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products. Via Benzinga Performance YTD -0.06% -0.06% 1 Month +2.63% +2.63% 3 Month +11.60% +11.60% 6 Month -2.50% -2.50% 1 Year +31.30% +31.30% More News Read More Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 03, 2024 From Innoviva, Inc. Via Business Wire 3 Under-$20 Stocks That Could Make You a Fortune May 31, 2024 Via InvestorPlace INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024 May 08, 2024 Via InvestorPlace Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress May 08, 2024 From Innoviva, Inc. Via Business Wire Innoviva to Participate in the BofA Securities Health Care Conference May 08, 2024 From Innoviva, Inc. Via Business Wire Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 April 24, 2024 From Innoviva Specialty Therapeutics Via Business Wire 5 Value Stocks In The Healthcare Sector March 04, 2024 Via Benzinga Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress February 29, 2024 From Innoviva, Inc. Via Business Wire If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names January 10, 2024 Via InvestorPlace Chart Of The Day: Innoviva - Individual Investor Favorite January 08, 2024 Via Talk Markets Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress November 01, 2023 From Innoviva, Inc. Via Business Wire Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea November 01, 2023 From Innoviva Specialty Therapeutics Via Business Wire A Look Into Healthcare Sector Value Stocks October 02, 2023 Via Benzinga Innoviva to Participate in the Cantor Global Healthcare Conference September 19, 2023 From Innoviva, Inc. Via Business Wire XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults September 18, 2023 From Innoviva, Inc. Via Business Wire Innoviva Appoints Stephen Basso as Chief Financial Officer August 25, 2023 From Innoviva, Inc. Via Business Wire Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress August 02, 2023 From Innoviva, Inc. Via Business Wire Overview Of Value Stocks In The Healthcare Sector July 31, 2023 Via Benzinga Why These 7 Stocks Are the Best Ways to Play Biotech Right Now July 11, 2023 Via InvestorPlace Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference June 06, 2023 From Innoviva, Inc. Via Business Wire AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter May 24, 2023 Via Benzinga Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use May 23, 2023 From Innoviva, Inc. Via Business Wire Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying May 16, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
